Engraftment and survival by mycophenolate mofetil (MMF) exposure. Overall survival (A), graft failure-free survival (B), neutrophil recovery (defined as >500 neutrophils/uL on 3 consecutive days post-HCT) (C), and platelet recovery (defined as >20,000 platelets/uL on 3 consecutive days post-HCT without transfusion in preceding 7 days) (D) do not vary with MMF exposure, except for neutrophil recovery, where the effect disappeared when only marrow grafts were analyzed. Donor CD3+ chimerism at days 28, 42, and 60 is significantly higher in patients with reduced MMF exposure, even accounting for graft type (E). Statistical significance depicted as: ns (p > 0.05), *, (p < 0.05), ** (p < 0.001), *** (p < 0.001), and **** (p < 0.0001).